Log in
NYSE:APHA

Aphria Stock Forecast, Price & News

$4.68
+0.02 (+0.43 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.56
Now: $4.68
$4.70
50-Day Range
$4.44
MA: $4.62
$4.92
52-Week Range
$1.95
Now: $4.68
$6.30
Volume1.89 million shs
Average Volume6.19 million shs
Market Capitalization$1.35 billion
P/E Ratio52.00
Dividend YieldN/A
Beta2.19
Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$179.29 million
Book Value$5.23 per share

Profitability

Net Income$-12,480,000.00

Miscellaneous

Employees300
Market Cap$1.35 billion
Next Earnings Date10/20/2020 (Estimated)
OptionableNot Optionable
$4.68
+0.02 (+0.43 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APHA News and Ratings via Email

Sign-up to receive the latest news and ratings for APHA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aphria (NYSE:APHA) Frequently Asked Questions

How has Aphria's stock been impacted by Coronavirus?

Aphria's stock was trading at $2.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, APHA shares have increased by 73.3% and is now trading at $4.68.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aphria?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aphria in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aphria
.

When is Aphria's next earnings date?

Aphria is scheduled to release its next quarterly earnings announcement on Tuesday, October 20th 2020.
View our earnings forecast for Aphria
.

How were Aphria's earnings last quarter?

Aphria Inc (NYSE:APHA) released its earnings results on Wednesday, July, 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.07. The business had revenue of $109.80 million for the quarter, compared to analysts' expectations of $105.64 million. Aphria had a negative return on equity of 0.30% and a net margin of 5.75%.
View Aphria's earnings history
.

What price target have analysts set for APHA?

8 equities research analysts have issued 1 year target prices for Aphria's stock. Their forecasts range from $7.00 to $11.00. On average, they expect Aphria's share price to reach $8.83 in the next year. This suggests a possible upside of 88.6% from the stock's current price.
View analysts' price targets for Aphria
.

Who are some of Aphria's key competitors?

What other stocks do shareholders of Aphria own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aphria investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), Tilray (TLRY), OrganiGram (OGI), NVIDIA (NVDA), Alibaba Group (BABA), KushCo (KSHB), Advanced Micro Devices (AMD) and HEXO (HEXO).

Who are Aphria's key executives?

Aphria's management team includes the following people:
  • Mr. Carl A. Merton, Chief Financial Officer
  • Ms. Megan McCrae, Director of Marketing
  • Mr. Irwin D. Simon, Interim CEO & Chairman
  • Mr. Jakob Ripshtein, Pres
  • Mr. Gary Leong, Chief Science Officer (Age 54)

What is Aphria's stock symbol?

Aphria trades on the New York Stock Exchange (NYSE) under the ticker symbol "APHA."

Who are Aphria's major shareholders?

Aphria's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.42%), Intact Investment Management Inc. (0.38%), TD Asset Management Inc. (0.31%), FMR LLC (0.31%), FMR LLC (0.31%) and AdvisorShares Investments LLC (0.20%).

Which institutional investors are selling Aphria stock?

APHA stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Advisor Group Holdings Inc., Private Advisor Group LLC, Toronto Dominion Bank, UBS Group AG, Actinver Wealth Management Inc., and AE Wealth Management LLC.

Which institutional investors are buying Aphria stock?

APHA stock was purchased by a variety of institutional investors in the last quarter, including Intact Investment Management Inc., Vanguard Group Inc., FMR LLC, FMR LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, AdvisorShares Investments LLC, Point72 Asset Management L.P., and TD Asset Management Inc..

How do I buy shares of Aphria?

Shares of APHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aphria's stock price today?

One share of APHA stock can currently be purchased for approximately $4.68.

How big of a company is Aphria?

Aphria has a market capitalization of $1.35 billion and generates $179.29 million in revenue each year. The company earns $-12,480,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Aphria employs 300 workers across the globe.

What is Aphria's official website?

The official website for Aphria is aphriainc.com.

How can I contact Aphria?

Aphria's mailing address is 245 TALBOT STREET W., LEAMINGTON A6, N8H 1N8.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.